Changes in serum lactate dehydrogenase as a prognostic factor in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.

IF 1.2 4区医学 Q3 OTORHINOLARYNGOLOGY

Acta Oto-Laryngologica Pub Date : 2024-05-01 Epub Date: 2024-08-10 DOI:10.1080/00016489.2024.2381631

Woo Hee Lee, Yukinori Takenaka, Kiyohito Hosokawa, Hirotaka Eguchi, Masami Suzuki, Takahito Fukusumi, Motoyuki Suzuki, Hidenori Inohara

{"title":"Changes in serum lactate dehydrogenase as a prognostic factor in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.","authors":"Woo Hee Lee, Yukinori Takenaka, Kiyohito Hosokawa, Hirotaka Eguchi, Masami Suzuki, Takahito Fukusumi, Motoyuki Suzuki, Hidenori Inohara","doi":"10.1080/00016489.2024.2381631","DOIUrl":null,"url":null,"abstract":"Background: Lactate dehydrogenase (LDH) is involved in the Warburg effect. Elevated serum LDH is a prognostic marker for metastatic solid cancer.Aim: To investigate the prognostic impact of serum LDH in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors (ICIs).Materials and methods: This retrospective study included 129 patients treated with ICIs between 2017 and 2023. The effects of pretreatment LDH, LDH at 3 months, and change in LDH during the first 3 months (ΔLDH) on overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method and Cox regression model.Results: The 1-year PFS and OS rates for high and low groups were 6.0% and 30.1% for pretreatment LDH (p = 0.044), 25.7% and 38.3% for on-treatment LDH (p = 0.079), and 14.3% and 38.7% for ΔLDH (p = 0.008), as well as 42.1% and 60.9% for pretreatment LDH (p = 0.109), 56.0% and 80.5% (p < 0.001) for on-treatment LDH, and 31.0% and 81.0% for ΔLDH (p < 0.001), respectively. ΔLDH was an independent prognostic factor for both PFS and OS.Conclusions and significance: ΔLDH can be used to predict ICI treatment outcomes and as a marker in deciding to continue ICI therapy.","PeriodicalId":6880,"journal":{"name":"Acta Oto-Laryngologica","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Oto-Laryngologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00016489.2024.2381631","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lactate dehydrogenase (LDH) is involved in the Warburg effect. Elevated serum LDH is a prognostic marker for metastatic solid cancer.

Aim: To investigate the prognostic impact of serum LDH in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors (ICIs).

Materials and methods: This retrospective study included 129 patients treated with ICIs between 2017 and 2023. The effects of pretreatment LDH, LDH at 3 months, and change in LDH during the first 3 months (ΔLDH) on overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method and Cox regression model.

Results: The 1-year PFS and OS rates for high and low groups were 6.0% and 30.1% for pretreatment LDH (p = 0.044), 25.7% and 38.3% for on-treatment LDH (p = 0.079), and 14.3% and 38.7% for ΔLDH (p = 0.008), as well as 42.1% and 60.9% for pretreatment LDH (p = 0.109), 56.0% and 80.5% (p < 0.001) for on-treatment LDH, and 31.0% and 81.0% for ΔLDH (p < 0.001), respectively. ΔLDH was an independent prognostic factor for both PFS and OS.

Conclusions and significance: ΔLDH can be used to predict ICI treatment outcomes and as a marker in deciding to continue ICI therapy.

查看原文本刊更多论文

血清乳酸脱氢酶的变化是接受免疫检查点抑制剂治疗的头颈部鳞状细胞癌患者的预后因素之一。

背景：乳酸脱氢酶（LDH乳酸脱氢酶（LDH）参与沃伯格效应。血清LDH升高是转移性实体癌的预后标志物。目的：研究血清LDH对接受免疫检查点抑制剂（ICIs）治疗的头颈部鳞状细胞癌患者预后的影响：这项回顾性研究纳入了2017年至2023年间接受ICIs治疗的129例患者。采用Kaplan-Meier法和Cox回归模型分析了治疗前LDH、3个月时LDH以及前3个月LDH变化（ΔLDH）对总生存期（OS）和无进展生存期（PFS）的影响：高组和低组的1年PFS和OS率分别为：治疗前LDH为6.0%和30.1%（P = 0.044），治疗中LDH为25.7%和38.3%（P = 0.079），ΔLDH为14.3%和38.7%（P = 0.008），治疗后LDH为42.1%和 60.9%（p = 0.109），治疗前 LDH 为 56.0%和 80.5%（p p 结论和意义：ΔLDH 可用于预测 ICI 治疗结果，并可作为决定是否继续 ICI 治疗的标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Oto-Laryngologica 医学-耳鼻喉科学

CiteScore

2.50

自引率

0.00%

发文量

审稿时长

3-6 weeks

期刊介绍： Acta Oto-Laryngologica is a truly international journal for translational otolaryngology and head- and neck surgery. The journal presents cutting-edge papers on clinical practice, clinical research and basic sciences. Acta also bridges the gap between clinical and basic research.